|
Sage Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. It has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. It targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. It has a portfolio of other compounds that target GABAA receptors, including SAGE-324.
Number of employees : 471 people.
|
|
| 2020 | 2021 | Delta | Novel Medicines | 1 114.20 | 100% | 6.31 | 100% | -99.43% |
USD in Million |
|
|
| 2020 | 2021 | Delta | United States | 1 114.20 | 100% | 6.31 | 100% | -99.43% |
USD in Million |
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
Stock A |
1 |
59,425,376 |
51,975,190 |
87.5% |
3,033 |
0.0% |
87.5% |
|
|
Name | Equities | % | Wellington Management Co. LLP | 6,995,000 |
11.8% | Biogen Inc. | 6,241,473 |
10.6% | The Vanguard Group, Inc. | 4,656,808 |
7.88% | Fidelity Management & Research Co. LLC | 3,514,883 |
5.95% | Bellevue Asset Management AG | 2,973,178 |
5.03% | SSgA Funds Management, Inc. | 2,835,356 |
4.80% | T. Rowe Price Associates, Inc. (Investment Management) | 2,158,504 |
3.65% | Artisan Partners LP | 1,521,580 |
2.58% | OppenheimerFunds, Inc. | 1,443,145 |
2.44% | BlackRock Fund Advisors | 1,309,094 |
2.22% |
|
Company contact information |
|
SAGE Therapeutics, Inc. 215 1st Street Cambridge, MA 02142 Phone : +1.617.299.8380 Fax : +1.617.299.8379 Web : http://www.sagerx.com
|
|
|
Sector Bio Therapeutic Drugs
| | 1st jan. | Capi. (M$) |
 | SAGE THERAPEUTICS, INC. | 1.36% | 2 562 |
| | | |
 | GILEAD SCIENCES, INC. | -9.08% | 82 747 |
 | VERTEX PHARMACEUTICALS | 37.98% | 76 740 |
 | REGENERON PHARMACEUTICALS, INC. | 0.76% | 68 030 |
 | WUXI APPTEC CO., LTD. | -22.47% | 39 407 |
 | BIONTECH SE | -41.02% | 36 949 |
 | GENMAB A/S | 0.99% | 23 720 |
 | ARGENX SE | 19.54% | 21 105 |
 | BEIGENE, LTD. | -33.63% | 18 606 |
 | NEUROCRINE BIOSCIENCES, INC. | 23.21% | 10 036 |
 | SAREPTA THERAPEUTICS, INC. | 21.04% | 9 545 |
 | KARUNA THERAPEUTICS, INC. | 99.41% | 8 736 |
 | LEGEND BIOTECH CORPORATION | -3.45% | 7 329 |
 | EXELIXIS, INC. | 5.63% | 6 215 |
 | HALOZYME THERAPEUTICS, INC. | 7.96% | 5 981 |
 | ASCENDIS PHARMA A/S | -28.05% | 5 402 |
 | PHARMAESSENTIA CORPORATION | 89.76% | 5 267 |
 | CEREVEL THERAPEUTICS HOLDINGS, INC. | -0.77% | 5 011 |
 | INTRA-CELLULAR THERAPIES, INC. | -1.60% | 4 862 |
 | ARROWHEAD PHARMACEUTICALS, INC. | -30.80% | 4 856 |
 | BIOCON LIMITED | -12.93% | 4 771 |
Connections : Sage Therapeutics, Inc.
|